Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AMRI has realigned its services to expand and integrate its in vitro biology services with its total drug discovery service platform as part of its SMARTSOURCING strategy.
Subscribe to our email newsletter
As a result of shifting market preferences for integrated drug discovery activities, the company will close its Bothell site, US, and transit the site’s biology capabilities and certain analytical capabilities to AMRI’s integrated discovery location in Singapore and analytical quality group in Albany, US, respectively.
AMRI is expected to incur certain one-time cash and non-cash charges around $11m and also save nearly $2m per annum due to the transition activities.
AMRI chairman, president and chief executive officer Thomas E. D’Ambra said by further aligning and integrating global biology services, the company continues to address and anticipate changes in the marketplace, strengthen its position as a provider of integrated drug discovery services.
"Already our SMARTSOURCING™ initiatives are proving effective as evidenced by expanded contract services opportunities; this next move provides us the potential to better pursue these opportunities as we enter 2013,” Ambra added.
”We will continue to focus on improving our cost structure and capabilities in order to build stronger and long-term relationships with existing and new customers."
The shutdown of Bothell operation is expected by the end of the first quarter of 2013.